Formulation Licenses
Registered finished dosage forms (FDF), transferable tech packages and in-development in-licensing pipelines · delivered per target-market approval pathway
Formulation (FDF)
Human Rabies Immunoglobulin
— · 200IU (2mL)
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB129)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Human Immunoglobulin (pH4) for Intravenous Injection
Injection · 1.25g/vial (5%, 25mL); 2.5g/vial (5%, 50mL); 5g/vial (5%, 100mL)
- Therapy
- Immunology & Inflammation
- Status
- Official FDF licensing catalog (UB128)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- To be assessed
Formulation (FDF)
Diclofenac Sodium Eye Drops
Eye Drops · 0.1%
- Therapy
- Ophthalmology
- Status
- Official FDF licensing catalog (UB124)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- To be assessed
Formulation (FDF)
Sodium Hyaluronate Eye Drops
Eye Drops · 0.4mL:1.2mg
- Therapy
- Ophthalmology
- Status
- Official FDF licensing catalog (UB122)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- To be assessed
Formulation (FDF)
Moxifloxacin Hydrochloride Eye Drops
Eye Drops · 5mL:24.4mg; 5mL:25mg; 0.4mL:1.2mg
- Therapy
- Ophthalmology
- Status
- Official FDF licensing catalog (UB121)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Levofloxacin Eye Drops
Eye Drops · 5mL:24.4mg
- Therapy
- Ophthalmology
- Status
- Official FDF licensing catalog (UB120)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Sildenafil Citrate Tablets
Tablets · 100mg
- Therapy
- Others > Men's Health
- Status
- Official FDF licensing catalog (UB118)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Levamlodipine Besylate Tablets
Tablets · 2.5mg
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB117)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Palonosetron Hydrochloride solution for Injection
for Injection · 5mL:0.25mg
- Therapy
- Anesthesiology
- Status
- Official FDF licensing catalog (UB116)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Bupivacaine Liposomal Injection
Injection · 133mg/10mL; 266mg/20mL
- Therapy
- Anesthesiology
- Status
- Official FDF licensing catalog (UB114)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Tolvaptan Tablets
Tablets · 15mg; 30mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB113)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Daptomycin for Injection
for Injection · 500mg
- Therapy
- Others > Dermatology
- Status
- Official FDF licensing catalog (UB112)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Caspofungin Acetate for Injection
for Injection · 50mg; 70mg
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB111)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, EU
Formulation (FDF)
Pegaspargase Injection
Injection · 5mL:3750IU; 2mL:1500IU
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB110)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Irinotecan Liposomal Injection
Injection · 40mg/2ml
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB109)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Paclitaxel (Albumin-Bound) for Injection
for Injection · 100mg
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB108)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- EU, United States
Formulation (FDF)
Megestrol Acetate Suspension
Suspension · 40mg
- Therapy
- Others > Women's Health
- Status
- Official FDF licensing catalog (UB107)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- South Korea
Formulation (FDF)
Oral adsorptive Charcoal
— · 2g
- Therapy
- Nephrology & Urology
- Status
- Official FDF licensing catalog (UB106)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- South Korea
Formulation (FDF)
Pelubiprofen Tablet
Tablet · 30mg
- Therapy
- Immunology & Inflammation
- Status
- Official FDF licensing catalog (UB105)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- South Korea
Formulation (FDF)
Amoxicillin and Clavulanate Potassium for Suspension (4:1)
Suspension · 250mg/62.5mg
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB088)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Lidocaine 4% Topical Anorectal Cream
Cream · 4%
- Therapy
- Anesthesiology
- Status
- Official FDF licensing catalog (UB087)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Lidocaine Hydrochloride Gel (2%)
Gel · 2%
- Therapy
- Anesthesiology
- Status
- Official FDF licensing catalog (UB086)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Efsubaglutide α
— · 1mg/0.5ml
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB079)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Thymalfasin for Injection
for Injection · 1.6mg
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB034)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- Philippines
Formulation (FDF)
Carbetocin Injection
Injection · 1ml:100μg
- Therapy
- Others > Women's Health
- Status
- Official FDF licensing catalog (UB033)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Visepegenatide Injection
Injection · 0.3ml:0.97mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB011)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Recombinant Human Erythropoietin Injection
Injection · 4000IU/1ml
- Therapy
- Nephrology & Urology
- Status
- Official FDF licensing catalog (UB009)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Recombinant Human Interleukin-11(Ⅰ) for Injection
for Injection · 1.5mg (1.2*10^7 AU)
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB008)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Reteplase
— · 18mg/10ml
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB007)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Heparin Sodium Injection
Injection · 5.0ml/5000IU; 5.0ml/25000IU
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB006)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Enoxaparin Sodium Injection
Injection · 0.2ml: 2000IU 0.3ml: 3000IU 0.4ml: 4000IU 0.6ml: 6000IU 0.8ml: 8000IU 1.0ml: 10000IU 0.8ml: 12000IU 1.0ml: 15000IU
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB005)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China, United States, EU
Formulation (FDF)
Nadroparin Calcium Injection
Injection · 0.4ml:4100AXaIU; 0.6ml:6150AXaIU
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB004)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Low Molecular Weight Heparin Sodium Injection
Injection · 0.2ml:2050AXaIU; 0.4ml:4100AXaIU
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB003)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Dalteparin Sodium Injection
Injection · 0.2ml:5000IU; 0.3ml:7500IU
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB002)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Semaglutide Tablets
Tablets · 3mg; 7mg; 14mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB001)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Licensing pipeline
YAP/TAZ-TEAD
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB954)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China, United States
Licensing pipeline
B/Plasma cell
—
- Therapy
- Immunology & Inflammation
- Status
- Candidate licensing (UB822)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
NET/DAT and GABA(A)R
—
- Therapy
- Neurology
- Status
- Candidate licensing (UB787)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
TAAR1 and 5-HT(2C)R
—
- Therapy
- Others > Psychiatry
- Status
- Candidate licensing (UB786)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
5-HT(2A)R and 5-HT(2C)R
—
- Therapy
- Others > Psychiatry
- Status
- Candidate licensing (UB785)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
VMAT2 and Sigma-1 Receptor
—
- Therapy
- Neurology
- Status
- Candidate licensing (UB784)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
UB783
—
- Therapy
- Gastroenterology & Hepatology
- Status
- Candidate licensing (UB783)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- EU
Licensing pipeline
UB782
—
- Therapy
- Nephrology & Urology
- Status
- Candidate licensing (UB782)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- EU
Licensing pipeline
GLP-1
—
- Therapy
- Metabolic & Endocrinology
- Status
- Candidate licensing (UB778)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
5‑HT₃ receptor
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB769)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
UB741
—
- Therapy
- Others > Respiratory
- Status
- Candidate licensing (UB741)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
UB729
—
- Therapy
- Others > Psychiatry
- Status
- Candidate licensing (UB729)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- United States
Licensing pipeline
UB714
—
- Therapy
- Neurology
- Status
- Candidate licensing (UB714)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China